BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL
American Journal of Hematology · 2024-09 · 99 (9) · 1721-1731
DOI: 10.1002/ajh.27385 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2024-06. Verfasst von Karin Bauer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Transcription Factors, Triazoles, Azepines. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund (FWF), Medical University of Vienna, Medizinische Universität Wien.
Abstract (Originalsprache)
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are life‐threatening hematopoietic malignancies characterized by clonal expansion of leukemic blasts in the bone marrow and peripheral blood. The epigenetic reader BRD4 and its downstream effector MYC have recently been identified as potential drug targets in human AML and ALL. We compared anti‐leukemic efficacies of the small‐molecule BET inhibitor JQ1 and the recently developed BRD4 degraders dBET1 and dBET6 in AML and ALL cells. JQ1, dBET1, and dBET6 were found to suppress growth and viability in all AML and ALL cell lines examined as well as in primary patient‐derived AML and ALL cells, including CD34 + /CD38 − and CD34 + /CD38 + leukemic stem and progenitor cells, independent of the type (variant) of leukemia or molecular driver expressed in leukemic cells. Moreover, we found that dBET6 overcomes osteoblast‐induced drug resistance in AML and ALL cells, regardless of the type of leukemia or the drug applied. Most promising cooperative or even synergistic drug combination effects were seen with dBET6 and the FLT3 ITD blocker gilteritinib in FLT3 ITD‐mutated AML cells, and with dBET6 and the multi‐kinase blocker ponatinib in BCR::ABL1 + ALL cells. Finally, all BRD4‐targeting drugs suppressed interferon‐gamma‐ and tumor necrosis factor‐alpha‐induced expression of the resistance‐related checkpoint antigen PD‐L1 in AML and ALL cells, including LSC. In all assays examined, the BRD4 degrader dBET6 was a superior anti‐leukemic drug compared with dBET1 and JQ1. Together, BRD4 degraders may provide enhanced inhibition of multiple mechanisms of therapy resistance in AML and ALL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria.
- Ihr Labor, Medical Diagnostic Laboratories, Vienna, Austria.
- Labor Europaplatz, Linz, Austria.
- Third Medical Department for Hematology and Oncology, Hanusch Hospital Vienna, Vienna, Austria.
- MLL Munich Leukemia Laboratory, Munich, Germany.
ORCID-Profile: Karin Bauer, Karoline V Gleixner, Wolfgang R Sperr, Peter Valent
Förderung
- Austrian Science Fund (FWF)
- Medical University of Vienna
- Medizinische Universität Wien
Zitieren
APA
Bauer, K., Hauswirth, A., Gleixner, K. V., Greiner, G., Thaler, J., Bettelheim, P., Filik, Y., Koller, E., Hoermann, G., Staber, P. B., Sperr, W. R., Keil, F., & Valent, P. (2024). BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL. American Journal of Hematology, 99(9), 1721-1731. https://doi.org/10.1002/ajh.27385
Vancouver
Bauer K, Hauswirth A, Gleixner KV, Greiner G, Thaler J, Bettelheim P, et al. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL. American Journal of Hematology. 2024;99(9):1721-1731. doi:10.1002/ajh.27385
BibTeX
@article{Bauer2024,
author = {Bauer, Karin and Hauswirth, Alexander and Gleixner, Karoline V and Greiner, Georg and Thaler, Johannes and Bettelheim, Peter and Filik, Yüksel and Koller, Elisabeth and Hoermann, Gregor and Staber, Philipp B and Sperr, Wolfgang R and Keil, Felix and Valent, Peter},
title = {BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {9},
pages = {1721--1731},
doi = {10.1002/ajh.27385}
}
EUVIMED